What the research found

A Citigroup survey cited by the Financial Times found that 28% of respondents reported using one of 12 unnamed peptides, with stated willingness to spend around $90 monthly. Extrapolating this across the US adult population yields a theoretical market size near $80 billion annually, though the survey methodology, sample size and peptide definitions remain unpublished.

Social-media analysis over 18 months showed substantial growth in peptide-related content. Mentions of specific peptides (GHK-Cu, MOTS-c, Semax, Selank, Epithalon) increased between 5- and 10-fold across major platforms. TikTok posts in peptide communities rose 712% between early and mid-2026—yet engagement per post fell 90% in the same window, suggesting volume growth without proportional audience interest.

The independent research and testing infrastructure underpinning this demand already exists. Community-driven efforts have catalogued nearly 1,730 vendors, over 9,800 laboratory tests and identified over 300 vendors with published results. This peer-review-like layer emerged largely outside formal regulation.

Why it matters for you

If you're tracking peptides on MyKine, you've likely benefited from the testing and vendor-reputation infrastructure this ecosystem built. Independent lab results, batch testing and vendor comparison—tools you use to assess product quality—originated from researchers and RUO communities, not pharmaceutical companies or telehealth platforms.

The growth in content and platforms also means more information is available but also more noise. A 90% drop in TikTok engagement despite a 7-fold increase in posts suggests the signal-to-noise ratio is deteriorating. When choosing peptide sources or interpreting claims about efficacy, distinguishing between marketing volume and substantive evidence becomes harder.

As institutional interest in peptides grows, the supply chain may consolidate or professionalize. This could improve oversight and safety standards—or it could restrict access to the RUO products and testing resources that have enabled independent optimization so far. How that transition unfolds will affect both availability and cost of what you can track and use.

Caveats

  • The Citigroup survey remains unpublished; sample size, questionnaire wording, date and peptide list are unknown
  • "Used" was not defined—unclear whether it includes prescription medications, supplements, or experimental research compounds
  • Social-media metrics (volume and engagement) do not measure actual sales, safety outcomes or clinical efficacy
  • Independent testing establishes identity and purity only; it does not verify sterility, safety profiles, fill accuracy or clinical effectiveness
  • Community reputation is not regulatory oversight; certificates can be falsified or mismatched to products
  • Forecasts for the 2026–2033 peptide market vary widely (50–294 billion USD) depending on category definitions and scope